Five Prime Therapeutics, Inc. (FPRX) CEO Aron Knickerbocker on Q2 2019 Results - Earnings Call Transcript

Five Prime Therapeutics, Inc. (FPRX)
Q2 2019 Earnings Conference Call
August 00, 2019 04:30 PM ET

Company Participants

Martin Forrest - VP of IR & Corporate Communications
Aron Knickerbocker - CEO
Dr. Helen Collins - CMO
David Smith - CFO

Conference Call Participants

Jonathan Chang - SVB Leerink
Timor Vanicus - Raymond James
Charles Xu - Guggenheim Securities
Chris Shibutani - Cowen
Tony Butler - Roth Capital Partners
Maryana Breitman - Goldman Sachs
Eric Joseph - JP Morgan
Nick Abbott - Wells Fargo

Operator

Welcome to the Five Prime Therapeutics Second Quarter 2019 Earnings Call. As a reminder, this conference call is being recorded.

I'd like now to introduce your host for today's conference, Martin Forrest, Vice President, Investor Relations and Corporate Communications. You may begin.

Martin Forrest

Thank you, Sarah. Good afternoon, everyone, and thank you for joining us. A press release with the Company's second quarter financial results was issued earlier today and can be found on our company website. Joining me today are Aron Knickerbocker, Chief Executive Officer; Dr. Helen Collins, Chief Medical Officer; and David Smith, Chief Financial Officer.

Today's conference call will include forward-looking statements under the Private Securities Litigation Reform Act of 1995, including statements regarding our research and development programs and financial outlook. Actual results may differ from those indicated by these forward-looking statements due to numerous factors, including those discussed in the Risk Factors section of our SEC filings. Our expectations and assumptions could change. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our views change.

I will now turn the call over to Aron.

Aron Knickerbocker

Thanks, Martin. Good afternoon and thanks for joining us today to review our progress and achievements during the second quarter and preview upcoming